Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet

M R McClung, P D Miller, J P Brown, J Zanchetta, M A Bolognese, C L Benhamou, A Balske, D E Burgio, J Sarley, L K McCullough, R R Recker, M R McClung, P D Miller, J P Brown, J Zanchetta, M A Bolognese, C L Benhamou, A Balske, D E Burgio, J Sarley, L K McCullough, R R Recker

Abstract

Dosing regimens of oral bisphosphonates are inconvenient and contribute to poor compliance. The bone mineral density response to a once weekly delayed-release formulation of risedronate given before or following breakfast was non-inferior to traditional immediate-release risedronate given daily before breakfast. Delayed-release risedronate is a convenient regimen for oral bisphosphonate therapy.

Introduction: We report the results of a randomized, controlled, clinical study assessing the efficacy and safety of a delayed-release (DR) 35 mg weekly oral formulation of risedronate that allows patients to take their weekly risedronate dose before or immediately after breakfast.

Methods: Women with postmenopausal osteoporosis were randomly assigned to receive risedronate 5 mg immediate-release (IR) daily (n = 307) at least 30 min before breakfast, or risedronate 35 mg DR weekly, either at least 30 min before breakfast (BB, n = 308) or immediately following breakfast (FB, n = 307). Bone mineral density (BMD), bone turnover markers (BTMs), fractures, and adverse events were evaluated. The primary efficacy variable was percent change from baseline in lumbar spine BMD at Endpoint.

Results: Two hundred fifty-seven subjects (83.7%) in the IR daily group, 252 subjects (82.1%) in the DR FB weekly group, and 258 subjects (83.8%) in the DR BB weekly group completed 1 year. Both DR weekly groups were determined to be non-inferior to the IR daily regimen. Mean percent changes in hip BMD were similar across groups. The magnitude of BTM response was similar across groups; some statistical differences were seen that were small and deemed by investigators to have no major clinical importance. The incidence of adverse events leading to withdrawal and serious adverse events were similar across treatment groups. All three regimens were well tolerated.

Conclusions: Risedronate 35 mg DR weekly is similar in efficacy and safety to risedronate 5 mg IR daily, and will allow patients to take their weekly risedronate dose immediately after breakfast.

Trial registration: ClinicalTrials.gov NCT00541658.

Figures

Fig. 1
Fig. 1
Disposition of subjects
Fig. 2
Fig. 2
Mean percent change from baseline ± SE in BMD over 1 year in women receiving risedronate 5 mg IR daily , 35 mg DRFB weekly , or 35 mg DRBB weekly . The Endpoint value is calculated using LOCF at Week 52. Asterisk statistically significant difference between IR daily and each of the DR weekly treatment groups
Fig. 3
Fig. 3
Mean percent change from baseline ± SE in bone turnover markers over 1 year in women receiving risedronate 5 mg IR daily , 35 mg DRFB weekly , or 35 mg DRBB weekly. The Endpoint value is calculated using LOCF at Week 52. Asterisk statistically significant difference between IR daily and each of the DR weekly treatment groups

References

    1. Merck & Co., Inc. Fosamax® Prescribing Information. . Accessed 18 March 2011
    1. Warner Chilcott. Actonel® Prescribing Information. . Accessed 18 March 2011
    1. Roche Therapeutics, Inc. Boniva® Prescribing Information. . Accessed 18 March 2011
    1. Ettinger B, Pressman A, Schein J, Chan J, Silver P, Connolly N. Alendronate use among 812 women: prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation. J Manag Care Pharm. 1998;4(5):488–492.
    1. Fleisch H (2000) Pharmacokinetics. In: Bisphosphonates in bone disease: from the laboratory to the patient. 4th ed. San Diego: Academic. p. 56–62
    1. Barrett J, Worth E, Bauss F, Epstein S. Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol. 2004;44:951–965. doi: 10.1177/0091270004267594.
    1. Ogura Y, Gohsho A, Cyong J-C, Orimo H. Clinical trial of risedronate in Japanese volunteers: a study on the effects of timing of dosing on absorption. J Bone Miner Metab. 2004;22(2):120–126. doi: 10.1007/s00774-003-0459-x.
    1. Agrawal S, Krueger DC, Engelke JA, et al. Between-meal risedronate does not alter bone turnover in nursing home residents. J Am Geriatr Soc. 2006;54(5):790–795. doi: 10.1111/j.1532-5415.2006.00696.x.
    1. Kendler DL, Ringe JD, Ste-Marie LG, et al. Risedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporosis. Osteoporos Int. 2009;20(11):1895–1902. doi: 10.1007/s00198-009-0893-2.
    1. Genant HK, Wu CY, Van Kuik C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8(9):1137–1148. doi: 10.1002/jbmr.5650080915.
    1. Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int. 2002;71(2):103–111. doi: 10.1007/s00223-002-2011-8.
    1. Reginster JY, Minne HW, Sorensen O, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000;11(1):83–91. doi: 10.1007/s001980050010.
    1. Delmas PD, McClung MR, Zanchetta JR, et al. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone. 2008;42(1):36–42. doi: 10.1016/j.bone.2007.09.001.
    1. European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. . Accessed 18 March 2011
    1. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA. 1999;282(14):1344–1352. doi: 10.1001/jama.282.14.1344.
    1. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344(5):333–340. doi: 10.1056/NEJM200102013440503.
    1. Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res. 2005;20(8):1315–1322. doi: 10.1359/JBMR.050313.
    1. Delmas PD, Silvano A, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one year results from the dosing intravenous administration study. Arthritis Rheum. 2006;54(6):1838–1846. doi: 10.1002/art.21918.
    1. McClung MR, Benhamou C-L, Man Z, et al. The efficacy and tolerability of a monthly dosing regimen of 75 mg risedronate dosed on 2 consecutive days a month for the treatment of postmenopausal osteoporosis-1 year study results [abstract] Osteoporos Int. 2007;18(Suppl 2):S217–S218.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel